LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.13 1.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.09

Max

1.17

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-34M 68M
Eelmine avamishind	-0.67
Eelmine sulgemishind	1.13

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. veebr 2026, 23:44 UTC

Kuumad aktsiad

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17. veebr 2026, 23:20 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17. veebr 2026, 22:57 UTC

Tulu

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 21:59 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17. veebr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. veebr 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17. veebr 2026, 23:19 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 23:15 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:58 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17. veebr 2026, 22:58 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17. veebr 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17. veebr 2026, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17. veebr 2026, 22:44 UTC

Tulu

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:42 UTC

Tulu

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 22:36 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17. veebr 2026, 22:36 UTC

Tulu

Santos Final Dividend 10.3 U.S. Cents/Security

17. veebr 2026, 22:36 UTC

Tulu

Santos FY Underlying Profit US$898 Million, Down 25%

17. veebr 2026, 22:35 UTC

Tulu

Santos FY Revenue US$4.94 Billion, Down 8%

17. veebr 2026, 22:35 UTC

Tulu

Correct: Santos FY Net Profit US$818 Million, Down 33%

17. veebr 2026, 22:35 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17. veebr 2026, 22:34 UTC

Tulu

Santos FY Net Profit US$818 Billion, Down 33%

17. veebr 2026, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17. veebr 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. veebr 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.